Alector/$ALEC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alector
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
- Ticker
- $ALEC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 103
- Headquarters
- South San Francisco, United States
- Website
- www.alector.com
Alector Metrics
BasicAdvanced
$340M
6.18
$0.37
-
-
Price and volume
Market cap
$340M
52-week high
$2.76
52-week low
$1.09
Average daily volume
5.3M
Financial strength
Current ratio
4.104
Quick ratio
3.916
Long term debt to equity
0.1
Total debt to equity
0.18
Profitability
EBITDA (TTM)
42.164
Gross margin (TTM)
29.06%
Net profit margin (TTM)
23.87%
Operating margin (TTM)
21.84%
Effective tax rate (TTM)
0.86%
Revenue per employee (TTM)
$1,680,000
Management effectiveness
Return on assets (TTM)
9.45%
Return on equity (TTM)
47.52%
Valuation
Price to earnings (TTM)
6.177
Price to revenue (TTM)
1.463
Price to book
2.21
Price to tangible book (TTM)
2.21
Price to free cash flow (TTM)
-1.692
Free cash flow yield (TTM)
-59.12%
Free cash flow per share (TTM)
-1.354
Growth
Revenue change (TTM)
151.23%
Earnings per share change (TTM)
-134.42%
3-year revenue growth (CAGR)
21.67%
3-year earnings per share growth (CAGR)
-39.77%
What the Analysts think about Alector
Analyst ratings (Buy, Hold, Sell) for Alector stock.
Analyst projections of the future price of Alector stock.
Bulls say / Bears say
Genentech has licensed AL050 and will take responsibility for its development, manufacturing and commercialisation, paying Alector $100 million upfront with further milestone and royalty potential. The deal brings a major partner to the programme while Alector retains its ABC platform rights outside GCase therapies. (SEC)
After the Genentech and Spur payments, Alector estimated cash of about $223.7 million at 30 September and says this should fund operations into 2029. That gives it more time to advance its remaining programmes before needing more capital. (SEC)
AL137 has completed IND-enabling studies and is Alector’s lead Alzheimer’s antibody, with a clinical trial planned for 2027. Its proposed monthly injection and brain-delivery design could offer a differentiated approach, although evidence so far is preclinical. (Alector)
Alector’s two GSK-partnered progranulin drugs suffered clinical setbacks: nivisnebart’s Phase 2 Alzheimer’s trial stopped for futility, following latozinemab’s Phase 3 failure. GSK has now terminated the collaboration, removing a major partner and the prospect of its related milestones. (Reuters)
The remaining pipeline has yet to demonstrate benefit in human trials: AL137 is still preclinical, while Alector’s tau siRNA evidence comes from non-human primates. Its investment case therefore depends on programmes with substantial development and efficacy risk ahead. (Alector)
Alector’s October share offering of 36.6 million shares at $2.05 each adds substantial dilution for existing shareholders. Further funding needs could put pressure on the share count again as the company advances its clinical-stage pipeline. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
Alector Financial Performance
Revenues and expenses
Alector Earnings Performance
Company profitability
Upcoming events
No upcoming events
Alector News
AllArticlesVideos
Funds containing Alector
Fund name | Fund size | $ALEC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.